Press Releases

Company News
Summary ToggleAcura Pharmaceuticals to Raise Approximately $7.6 Million From Institutional Healthcare Investors
Jul 01, 2015
PALATINE, IL -- (Marketwired) -- 07/01/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced it has entered into a Securities Purchase Agreement with certain institutional investors to sell 9,790,000 shares of common stock at a price of $0.78 per share, payable at closing.

Read more

Summary ToggleAcura Pharmaceuticals USPTO Issues Notice of Allowance for Novel Limitx(TM) Abuse Deterrent Technology
Jun 29, 2015

New Oral Opioid Abuse Technology

Read more

Summary ToggleAcura Pharmaceuticals Partners Its Methamphetamine Resistant Impede(R) Technology
Jun 16, 2015
PALATINE, IL -- ( Marketwired ) -- 06/16/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that Acura has entered into a License and Development Agreement with Bayer Healthcare LLC to provide an exclusive worldwide license to Acura's IMPEDE technology for use in an undisclosed

Read more

Summary ToggleAcura Pharmaceuticals Announces First Quarter 2015 Financial Results
May 04, 2015
PALATINE, IL -- ( Marketwired ) -- 05/04/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the first quarter ended March 31, 2015 .

Read more

Summary ToggleAcura Pharmaceuticals to Host First Quarter 2015 Financial Results Conference Call on May 5, 2015
Apr 21, 2015
PALATINE, IL -- ( Marketwired ) -- 04/21/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs ,  today announced that the Company plans to report financial results for first quarter 2015 following the close of financial markets on

Read more

Summary ToggleAcura Pharmaceuticals to Develop Abuse Deterrent Hydrocodone With Acetaminophen Tablets With Limitx(TM) Technology
Apr 09, 2015

Immediate-Release Tablets Intended to Address Excess Oral Consumption

Read more

Summary ToggleAcura Pharmaceuticals Reports Successful Topline Results From Nexafed(R) Extended-Release Clinical Study
Mar 23, 2015
PALATINE, IL -- ( Marketwired ) -- 03/23/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , today announced preliminary topline results from a pilot clinical study which demonstrated bioequivalence of one formulation of NEXAFED (pseudoephedrine HCl) extended-release tablets to Sudafed® 12-Hour

Read more

Summary ToggleAcura Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results
Mar 02, 2015
PALATINE, IL -- ( Marketwired ) -- 03/02/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the year and three months ended December 31, 2014 .

Read more

Summary ToggleAcura Pharmaceuticals to Host 2014 Financial Results Conference Call on March 3, 2015
Feb 23, 2015
PALATINE, IL -- (Marketwired) -- 02/23/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for 2014 following the close of financial markets on Monday, March 2,

Read more

Summary ToggleAcura Pharmaceuticals Initiates Clinical Study of Meth-Resistant Nexafed(R) Extended-Release Formulations
Feb 16, 2015

Products Employ Improved Impede(R) 2.0 Technology

Read more

Summary ToggleAcura Pharmaceuticals Expands Meth-Resistant Decongestant Line With NEXAFED(R) Sinus Pressure + Pain
Feb 05, 2015

New Combination Sinus Pain and Congestion Product Will Utilize NEXAFED's IMPEDE(R) Meth-Deterring Technology

Read more

Summary ToggleAcura Pharmaceuticals Partners With Egalet Corporation to Commercialize Immediate Release Oxycodone Product Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology
Jan 08, 2015
PALATINE, IL -- (Marketwired) -- 01/08/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR)  today announced that the Company has entered into a Collaboration and License Agreement (the "Agreement") with Egalet US, Inc. and Egalet Ltd. (together "Egalet", subsidiaries of Egalet Corporation (NASDAQ:

Read more

Summary ToggleAcura Pharmaceuticals Acknowledges Distribution of Nexafed(R) by Kmart Pharmacy
Dec 23, 2014
PALATINE, IL -- (Marketwired) -- 12/23/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , today acknowledged the announcement by Kmart Pharmacy that Kmart is stocking NEXAFED [pseudoephedrine hydrochloride (HCl)], Acura's next generation pseudoephedrine with methamphetamine-resistant IMPEDE

Read more

Summary ToggleAcura Pharmaceuticals Receives Additional U.S. Patent for Abuse Deterrent Drug Formulations
Dec 08, 2014

First Patent Encompassing the IMPEDE(R) Technology

Read more

Summary ToggleAcura Pharmaceuticals Announces Third Quarter 2014 Financial Results
Nov 03, 2014
PALATINE, IL -- (Marketwired) -- 11/03/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2014 .

Read more

Summary ToggleAcura Pharmaceuticals to Host Third Quarter 2014 Financial Results Conference Call on November 4, 2014
Oct 28, 2014
PALATINE, IL -- (Marketwired) -- 10/28/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the third quarter 2014 following the close of financial markets on

Read more

Summary ToggleAcura Pharmaceuticals Provides Update on Its Hydrocodone Bitartrate With Acetaminophen Tablets Development
Oct 16, 2014
PALATINE, IL -- (Marketwired) -- 10/16/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR)  announced today that the US Food and Drug Administration (FDA) has denied on procedural grounds Acura's appeal of the position taken by Division of Anesthesia , Analgesia, and Addiction Products (DAAAP) that

Read more

Summary ToggleAcura Pharmaceuticals Hydrocodone Bitartrate With Acetaminophen Tablets Meet Clinical Endpoints
Sep 29, 2014
PALATINE, IL -- (Marketwired) -- 09/29/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announced today preliminary results from three clinical studies for its abuse deterrent AVERSION® hydrocodone bitartrate with acetaminophen (AVERSION H/A) development product with the key study demonstrating

Read more

Displaying 55 - 72 of 143 results